0 Commentarii
0 Distribuiri
734 Views
0 previzualizare
Căutare
Descoperă oameni noi, creează noi conexiuni și faceti-va noi prieteni
-
Vă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
-
Crizotinib Drugs Market Growing at 6.7% CAGR Through 2034According to a new report from Intel Market Research, the global Crizotinib Drugs market was valued at USD 582.4 million in 2025 and is projected to reach USD 1,043.7 million by 2034, growing at a CAGR of 6.7% during the forecast period (2026–2034). This growth is propelled by the rising global incidence of lung cancer, increasing adoption of molecular diagnostic testing for genetic...0 Commentarii 0 Distribuiri 1K Views 0 previzualizare
-
Global Multi-target MET TKIs Market Growing at 7.6% CAGR Through 2034According to a new report from Intel Market Research, the global Multi-target MET TKIs market was valued at USD 1.52 billion in 2025 and is projected to reach USD 3.18 billion by 2034, growing at a CAGR of 7.6% during the forecast period (2026–2034). This growth is propelled by the rising global incidence of non-small cell lung cancer and medullary thyroid cancer, precision oncology...0 Commentarii 0 Distribuiri 1K Views 0 previzualizare
-
TKIs for Breast Cancer Market Growing at 7.3% CAGR Through 2034According to a new report from Intel Market Research, the global TKIs for Breast Cancer market was valued at USD 1.82 billion in 2025 and is projected to reach USD 3.74 billion by 2034, growing at a CAGR of 7.3% during the forecast period (2025–2034). This growth is propelled by the rising global incidence of breast cancer, growing adoption of precision oncology, and increasing regulatory...0 Commentarii 0 Distribuiri 1K Views 0 previzualizare
-
United States ADC for Solid Tumors Market Growing at 8.9% CAGR Through 2034The United States Antibody‑Drug Conjugate (ADC) for Solid Tumors market size was valued at approximately USD 0.55 billion in 2025. The market is projected to grow from approximately USD 0.58 billion in 2026 to around USD 1.04 billion by 2034, exhibiting a CAGR of about 8.9% during the forecast period. Antibody‑Drug Conjugates are targeted therapeutics that combine a monoclonal antibody that...0 Commentarii 0 Distribuiri 11 Views 0 previzualizare